通过大数据和组合少量射击学习来提高早期阿尔茨海默病检测
IEEE journal of biomedical and health informatics
|October 2, 2024
概括
这项研究介绍了一种先进的阿尔茨海默病检测方法,使用大数据,预先训练的卷积神经网络 (CNN) 和少数镜头学习 (FSL). 新的整体方法实现了高准确性,克服了早期诊断的数据稀缺性挑战.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 医疗成像医学成像
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性脑部疾病,导致显著的记忆障碍.
- 精确的AD检测受到有限的标记医疗数据和隐私问题所阻碍.
- 现有的方法在数据稀缺和疾病复杂性方面扎.
研究的目的:
- 开发一种准确和强大的阿尔茨海默病检测方法.
- 为了应对AD诊断中有限的标记医疗数据的挑战.
- 为了利用大数据和短暂学习 (FSL) 来提高AD检测准确性.
主要方法:
- 一种集体学习方法,将各种预训练的卷积神经网络 (CNN) 集成为编码器.
- 利用原型网络 (ProtoNet),一个短暂的学习 (FSL) 方法,以增强特征提取.
- 纳入类意识损失和损失,以精确分类AD进展.
主要成果:
- 在Kaggle阿尔茨海默氏症数据集上达到99.72%,在ADNI数据集上达到99.86%的高准确率.
- 与现有最先进的方法相比,表现出优越的性能.
- 验证了该方法的有效性和现实世界的临床应用潜力.
结论:
- 拟议的集体FSL方法有效地解决了阿尔茨海默病检测中的数据稀缺问题.
- 预先训练有素的CNN和新的损失函数的整合显著提高了诊断准确度.
- 这种方法显示出早期和准确的阿尔茨海默病诊断的巨大潜力.
相关概念视频
01:26Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
01:30Dementia
99
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
99
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170